Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FUSION PHARMACEUTICALS INC.

(FUSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fusion Pharmaceuticals : To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

09/23/2021 | 04:11pm EDT

HAMILTON, ON and BOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 2:40pm ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2021-cantor-fitzgerald-virtual-global-healthcare-conference-301384279.html

SOURCE Fusion Pharmaceuticals Inc.


© PRNewswire 2021
All news about FUSION PHARMACEUTICALS INC.
10/20FUSION PHARMACEUTICALS : Announces Presentation of Preclinical Data Supporting its FPI-196..
PR
09/29FUSION PHARMACEUTICALS : Names Mohit Rawat as President and Chief Business Officer
MT
09/28FUSION PHARMACEUTICALS : Appoints Mohit Rawat as President and Chief Business Officer
PR
09/28Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer
CI
09/23FUSION PHARMACEUTICALS : To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcar..
PR
09/21FUSION PHARMACEUTICALS : Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Busines..
PR
09/21FUSION PHARMACEUTICALS : Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Busines..
AQ
09/21Fusion Pharmaceuticals Inc. Appoints Eric S. Hoffman as Senior Vice President, Business..
CI
09/02FUSION PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
PR
08/31FUSION PHARMACEUTICALS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
More news
Analyst Recommendations on FUSION PHARMACEUTICALS INC.
More recommendations